Analysts Expect Revance Therapeutics Inc (RVNC) Will Post Quarterly Sales of $80,000.00

Wall Street brokerages expect Revance Therapeutics Inc (NASDAQ:RVNC) to report sales of $80,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Revance Therapeutics’ earnings, with the highest sales estimate coming in at $80,000.00 and the lowest estimate coming in at $70,000.00. Revance Therapeutics also reported sales of $80,000.00 in the same quarter last year. The business is scheduled to report its next quarterly earnings results on Monday, February 26th.

On average, analysts expect that Revance Therapeutics will report full year sales of $80,000.00 for the current financial year, with estimates ranging from $300,000.00 to $400,000.00. For the next fiscal year, analysts forecast that the company will post sales of $430,000.00 per share, with estimates ranging from $200,000.00 to $600,000.00. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same period last year, the firm posted ($0.64) EPS. The business’s revenue was up .0% compared to the same quarter last year.

Several equities research analysts recently weighed in on RVNC shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a report on Tuesday, September 26th. Mizuho upped their price objective on shares of Revance Therapeutics from $37.00 to $54.00 and gave the stock a “buy” rating in a report on Wednesday, December 6th. Guggenheim started coverage on shares of Revance Therapeutics in a report on Tuesday, December 5th. They issued a “buy” rating and a $42.00 price objective for the company. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Revance Therapeutics in a report on Friday, October 27th. Finally, SunTrust Banks upped their price objective on shares of Revance Therapeutics to $53.00 and gave the stock a “buy” rating in a report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $44.30.

In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total value of $189,544.00. Following the completion of the sale, the chief executive officer now directly owns 133,188 shares of the company’s stock, valued at approximately $3,321,708.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark J. Foley purchased 20,000 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was acquired at an average cost of $26.96 per share, with a total value of $539,200.00. Following the completion of the acquisition, the director now directly owns 6,000 shares in the company, valued at approximately $161,760. The disclosure for this purchase can be found here. Corporate insiders own 18.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Revance Therapeutics by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after acquiring an additional 63,505 shares during the last quarter. State Street Corp lifted its holdings in Revance Therapeutics by 0.6% in the 2nd quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock valued at $11,944,000 after acquiring an additional 2,637 shares during the last quarter. PointState Capital LP lifted its holdings in Revance Therapeutics by 58.5% in the 2nd quarter. PointState Capital LP now owns 438,200 shares of the biopharmaceutical company’s stock valued at $11,568,000 after acquiring an additional 161,700 shares during the last quarter. FMR LLC lifted its holdings in Revance Therapeutics by 2.8% in the 2nd quarter. FMR LLC now owns 325,900 shares of the biopharmaceutical company’s stock valued at $8,604,000 after acquiring an additional 9,000 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Revance Therapeutics by 19.9% in the 2nd quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock valued at $8,418,000 after acquiring an additional 52,940 shares during the last quarter. 76.69% of the stock is owned by institutional investors.

Revance Therapeutics (NASDAQ RVNC) opened at $33.55 on Thursday. Revance Therapeutics has a 1-year low of $18.00 and a 1-year high of $37.45. The stock has a market cap of $1,040.00, a price-to-earnings ratio of -8.81 and a beta of 1.62.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/18/analysts-expect-revance-therapeutics-inc-rvnc-will-post-quarterly-sales-of-80000-00.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply